UY35368A - Péptidos y composiciones para el tratamiento de daño articular - Google Patents

Péptidos y composiciones para el tratamiento de daño articular

Info

Publication number
UY35368A
UY35368A UY0001035368A UY35368A UY35368A UY 35368 A UY35368 A UY 35368A UY 0001035368 A UY0001035368 A UY 0001035368A UY 35368 A UY35368 A UY 35368A UY 35368 A UY35368 A UY 35368A
Authority
UY
Uruguay
Prior art keywords
compositions
peptides
treatment
articular damage
damage
Prior art date
Application number
UY0001035368A
Other languages
English (en)
Inventor
Johnson Kristen
Shi Jian
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of UY35368A publication Critical patent/UY35368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención proporciona nuevos polipéptidos resistentes a la proteasa, así como composiciones y métodos para tratar, mejorar o prevenir condiciones relacionadas con daño articular, incluyendo lesión aguda de articulaciones y artritis.
UY0001035368A 2013-03-08 2014-03-06 Péptidos y composiciones para el tratamiento de daño articular UY35368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10

Publications (1)

Publication Number Publication Date
UY35368A true UY35368A (es) 2014-10-31

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035368A UY35368A (es) 2013-03-08 2014-03-06 Péptidos y composiciones para el tratamiento de daño articular

Country Status (39)

Country Link
US (4) US9649359B2 (es)
EP (2) EP3391900A1 (es)
JP (3) JP6567429B2 (es)
KR (1) KR102267341B1 (es)
CN (2) CN111808182A (es)
AP (1) AP2015008675A0 (es)
AU (3) AU2014225348B2 (es)
BR (2) BR112015021269B1 (es)
CA (1) CA2903448C (es)
CL (1) CL2015002443A1 (es)
CO (1) CO7461145A2 (es)
CR (2) CR20200290A (es)
CU (1) CU24301B1 (es)
CY (1) CY1120729T1 (es)
DK (1) DK2964250T3 (es)
EA (1) EA035158B1 (es)
EC (1) ECSP15042898A (es)
ES (1) ES2684349T3 (es)
HK (1) HK1214754A1 (es)
HR (1) HRP20181269T1 (es)
HU (1) HUE038499T2 (es)
IL (1) IL240727B (es)
JO (1) JO3564B1 (es)
LT (1) LT2964250T (es)
MX (1) MX365157B (es)
MY (1) MY173172A (es)
NZ (1) NZ711037A (es)
PE (1) PE20151528A1 (es)
PH (1) PH12015501983B1 (es)
PL (1) PL2964250T3 (es)
PT (1) PT2964250T (es)
RS (1) RS57446B1 (es)
SG (1) SG11201506490TA (es)
SI (1) SI2964250T1 (es)
TN (1) TN2015000385A1 (es)
TW (1) TWI634124B (es)
UY (1) UY35368A (es)
WO (1) WO2014138687A1 (es)
ZA (1) ZA201505966B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160951A (en) 2009-07-14 2017-03-31 Scripps Research Inst Mesenchymal stem cell differentiation
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
KR102117501B1 (ko) 2016-10-24 2020-06-01 스미또모 가가꾸 가부시키가이샤 세퍼레이터 및 세퍼레이터를 포함하는 이차 전지
JP2019535707A (ja) * 2016-11-14 2019-12-12 ノバルティス アーゲー 軟骨損傷および関節炎の処置のための方法および組成物
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
AU2019309727B2 (en) 2018-07-25 2021-12-23 Novartis Ag NLRP3 inflammasome inhibitors
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
CN118251594A (zh) 2021-11-10 2024-06-25 诺华股份有限公司 用于确定angptl多肽的生物活性的方法
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1159419A1 (en) 1999-03-08 2001-12-05 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ATE408699T1 (de) 1999-03-10 2008-10-15 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ATE368110T1 (de) 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
DE60141236D1 (de) 2000-10-16 2010-03-18 Genentech Inc Behandlungsverfahren unter Verwendung von WISP-Polypeptiden
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AU2002348286B2 (en) 2001-11-16 2008-04-03 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 Angptl3
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
ATE526414T1 (de) 2002-10-16 2011-10-15 Scripps Research Inst Ortsspezifische einbindung von ketoaminosäuren in proteine
JP4752001B2 (ja) 2002-10-16 2011-08-17 ザ スクリプス リサーチ インスティチュート 糖蛋白質合成
ATE542894T1 (de) 2003-04-17 2012-02-15 Scripps Research Inst Ausweitung des eukaryotischen genetischen codes
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
US7527943B2 (en) 2003-07-07 2009-05-05 The Scripps Research Institute Compositions of orthogonal glutamyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
DE602004027770D1 (de) 2003-07-07 2010-07-29 Scripps Research Inst Zusammensetzungen aus orthogonalen Lysyl-TRNA- und Aminoacyl-TRNA-Synthetasepaaren und deren Verwendung
CN101151366B (zh) 2004-09-21 2012-12-19 斯克利普斯研究院 将炔基氨基酸体内掺入真细菌的蛋白
MX2007004892A (es) 2004-10-27 2007-08-16 Scripps Research Inst Componentes de traduccion ortogonales para la incorporacion in vivo de aminoacidos no naturales.
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7807464B2 (en) 2005-05-24 2010-10-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
ES2432391T3 (es) 2006-03-09 2013-12-03 The Scripps Research Institute Sistema para la expresión de componentes de traducción ortogonales en células huésped eubacterianas
EP2386306A1 (en) 2006-12-06 2011-11-16 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8575397B2 (en) 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
MY160951A (en) * 2009-07-14 2017-03-31 Scripps Research Inst Mesenchymal stem cell differentiation
JP6161541B2 (ja) 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CA2877886A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics comprising heparin binding protein
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation

Also Published As

Publication number Publication date
BR112015021269B1 (pt) 2023-04-11
CR20150466A (es) 2015-10-27
EA201591661A1 (ru) 2015-12-30
PH12015501983A1 (en) 2016-01-11
HUE038499T2 (hu) 2018-10-29
CU24301B1 (es) 2017-12-08
PT2964250T (pt) 2018-10-19
JO3564B1 (ar) 2020-07-05
IL240727B (en) 2019-12-31
EP3391900A1 (en) 2018-10-24
MY173172A (en) 2020-01-02
NZ711037A (en) 2018-07-27
KR102267341B1 (ko) 2021-06-21
US20170252407A1 (en) 2017-09-07
RS57446B1 (sr) 2018-09-28
JP2021178841A (ja) 2021-11-18
CR20200290A (es) 2020-08-27
CA2903448C (en) 2021-03-23
JP6567429B2 (ja) 2019-08-28
AP2015008675A0 (en) 2015-08-31
AU2014225348B2 (en) 2016-03-31
HK1214754A1 (zh) 2016-08-05
CY1120729T1 (el) 2019-12-11
BR122016021558B1 (pt) 2023-03-28
EP2964250A1 (en) 2016-01-13
US11179442B2 (en) 2021-11-23
AU2014225348A1 (en) 2015-09-10
CN111808182A (zh) 2020-10-23
JP6918871B2 (ja) 2021-08-11
US10328126B2 (en) 2019-06-25
IL240727A0 (en) 2015-10-29
HRP20181269T1 (hr) 2018-10-19
JP2016510763A (ja) 2016-04-11
ZA201505966B (en) 2017-03-29
PL2964250T3 (pl) 2018-10-31
CO7461145A2 (es) 2015-11-30
AU2016277608A1 (en) 2017-01-12
WO2014138687A1 (en) 2014-09-12
BR122016021558A2 (pt) 2019-07-30
CN105025917B (zh) 2020-08-18
EA035158B1 (ru) 2020-05-06
US20160008433A1 (en) 2016-01-14
CU20150097A7 (es) 2016-05-30
US9649359B2 (en) 2017-05-16
AU2016277608B2 (en) 2018-04-05
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
MX2015011963A (es) 2015-12-09
BR112015021269A2 (pt) 2017-10-10
US20220184182A1 (en) 2022-06-16
MX365157B (es) 2019-05-24
CA2903448A1 (en) 2014-09-12
LT2964250T (lt) 2018-07-25
AU2016203028A1 (en) 2016-05-26
EP2964250B1 (en) 2018-05-16
JP2020015725A (ja) 2020-01-30
KR20150125712A (ko) 2015-11-09
DK2964250T3 (da) 2018-08-06
ECSP15042898A (es) 2019-03-29
AU2016203028B2 (en) 2017-02-02
AU2016203028C1 (en) 2017-06-01
TW201444865A (zh) 2014-12-01
CN105025917A (zh) 2015-11-04
ES2684349T3 (es) 2018-10-02
TWI634124B (zh) 2018-09-01
CL2015002443A1 (es) 2016-05-20
PH12015501983B1 (en) 2016-01-11
US20200268849A1 (en) 2020-08-27
SG11201506490TA (en) 2015-09-29
TN2015000385A1 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
CR20150466A (es) Péptidos y composiciones para el tratamiento de daño articular
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
BR112017010177A2 (pt) composição para tratamento de tecido
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
BR112017013579A2 (pt) método para uso de uma cepa de bacillus subtilis ou bacillus pumilus para tratar ou impedir a doença do abacaxi.
BR112017018574A2 (pt) métodos para o tratamento de doenças

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230915